Horizon Discovery Group plc Grant of options (0538H)

TIDMHZD

RNS Number : 0538H

Horizon Discovery Group plc

12 November 2018

Horizon Discovery Group plc

12 November 2018

Horizon Discovery Group plc

Cambridge, UK, 12 November 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that the following options were granted over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to its CEO on 9 November 2018 in accordance with the Company's Long Term Incentive Plan:

 
 Director       Number of Ordinary Shares     Exercise price per share 
                 over which options granted 
 Terry Pizzie   325,000                       GBP2.00 
               ----------------------------  ------------------------- 
 

The options will vest as follows:

   --     25% on the third anniversary of the date of grant; 
   --     25% on the fourth anniversary of the date of grant; and 
   --    50% on the fifth anniversary of the date of grant. 

The options granted are equivalent to 0.22 percent of the Company's existing issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 
 1     Details of the person discharging managerial 
        responsibilities/person closely associated 
 a)    Name                         Terry Pizzie 
      ---------------------------  ----------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------- 
 a)    Position/status              Chief Executive Officer 
      ---------------------------  ----------------------------------- 
 b)    Initial notification         Initial Notification 
        /Amendment 
      ---------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or 
        auction monitor 
      ---------------------------------------------------------------- 
 a)    Name                         Horizon Discovery Group plc 
      ---------------------------  ----------------------------------- 
 b)    Legal Entity                 213800L812B9NI5M3G89 
        Identifier 
      ---------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be 
        repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; 
        and (iv) each place where transactions have 
        been conducted 
      ---------------------------------------------------------------- 
 a)    Description                  Ordinary shares of 1 pence each 
        of the financial 
        instrument, 
        type of instrument 
                                     GB00BK8FL363 
        Identification 
        code 
      ---------------------------  ----------------------------------- 
 b)    Nature of                    Grant of share options 
        the transaction 
      ---------------------------  ----------------------------------- 
 c)    Currency                     GBP 
      ---------------------------  ----------------------------------- 
 d)    Price(s) and                     Price(s)          Volume(s) 
        volume(s) 
      ---------------------------  -----------------  ---------------- 
                          N/A                              325,000 
  --------------------------------------------------  ---------------- 
 
 e)    Aggregated 
        information 
        - Aggregated                  325,000 
        volume                        N/A 
        - Price                       N/A 
        - Aggregated 
        total 
      ---------------------------  ----------------------------------- 
 f)    Date of the                  9 November 2018 
        transaction 
      ---------------------------  ----------------------------------- 
 g)    Place of the                 London Stock Exchange, AIM 
        transaction 
      ---------------------------  ----------------------------------- 
 

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Richard Vellacott, Chief Financial Officer

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBGBDBIDBBGID

(END) Dow Jones Newswires

November 12, 2018 05:33 ET (10:33 GMT)